Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KIF11 | P52732 | 10/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9962196 | 0.90 | MAPT (0.49) | TP53MAPTSMN1; SMN2KIF11SIRT1 | |
| SCHEMBL12978466 | 0.84 | TP53 (0.45) | TP53MAPTSMN1; SMN2KIF11SIRT1 | |
| SCHEMBL16302704 | 0.82 | TP53 (0.44) | TP53MAPTSMN1; SMN2KIF11SIRT1 | |
| SCHEMBL9962199 | 0.82 | MAPT (0.48) | TP53MAPTSMN1; SMN2KIF11SIRT1 | |
| SCHEMBL9962158 | 0.82 | MAPT (0.49) | TP53MAPTSMN1; SMN2KIF11SIRT1 | |
| SCHEMBL9962229 | 0.82 | MAPT (0.49) | TP53MAPTSMN1; SMN2KIF11SIRT1 | |
| SCHEMBL764639 | 0.81 | TP53 (0.49) | TP53MAPTSMN1; SMN2KIF11SIRT1 | |
| SCHEMBL9962197 | 0.81 | MAPT (0.47) | TP53MAPTSMN1; SMN2KIF11SIRT1 | |
| SCHEMBL765111 | 0.80 | TP53 (0.59) | TP53MAPTSMN1; SMN2KIF11ABCG2 | |
| SCHEMBL8403050 | 0.80 | ABCG2 (0.57) | TP53MAPTSMN1; SMN2KIF11SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2434891-B9 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2021-05-05 | — | — | EP | disclosed |